Roivant Splashes Cash Again To License GSK Skin Disorder Drug

The UK drug maker is tightening its R&D focus by selling on the psoriasis and atopic dermatitis investigational drug tapinarof to Dermavant, banking a hefty £150m up front and possibly another £100m after that.

Gold
Riches under the Roivant umbrella • Source: Shutterstock

An extremely busy week for the Roivant Sciences GMBH umbrella of companies has ended with its Dermavant Sciences unit paying GlaxoSmithKline PLC £150m up front to get the rights to its Phase III-ready psoriasis and eczema candidate tapinarof.

As well as the initial fee, Dermavant has agreed to a potential future milestone payment of £100m to get hold of tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By 

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.